Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Revenue · Q3 FY2026 · quarter ended Mar 2026

Revenue of $23.19M in Q3 FY2026

Q3 FY2026 revenue was $23.19M. Trailing-twelve-month revenue was $135.16M. Over 3 fiscal years it compounded at +5.0% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $75.12M (-41.7%) for the fiscal year ending May 2026, a slowdown from the +0.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.19M-47.8% QoQ
Last fiscal yearMay 2025
$128.87M+0.5% YoY
LTMMar 2026
$135.16M— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.5%-41.7%-42.2 pp
3-year CAGR+5.0%+0.4%-4.7 pp
5-year CAGR+7.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
128.87M USD
Year-over-year change
+0.5%
4-year CAGR
+6.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Over three fiscal years its annual growth of +5.0% compares with a peer median of +13.2%.
LFCR Competitors
Revenue for LFCR and competitors
Company Period LTM YoY 3-year CAGR
CGCCanopy Growth CorporationLTM Mar 2026CA$312.34M CAD+16.1%+13.2%
ACBAurora Cannabis Inc.LTM Mar 2026CA$310.87M CAD-9.4%+12.8%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$135.16M USD—+5.0%
SGHTSight Sciences, Inc.LTM Mar 2026$79.55M USD+1.8%+2.7%
CVRXCVRx, Inc.LTM Mar 2026$59.07M USD+11.7%+36.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026$41.8M USD+9.3%-0.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026€13.44M EUR-29.2%+62.0%
BIOABioAge Labs, Inc.LTM Mar 2026$10.32M USD+611.0%—
IMMPImmutep LimitedFY2025A$5.04M AUD+31.3%+209.4%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$0 USD——
Peer median (excluding LFCR) —+10.5%+13.2%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue100.87M111.27M103.27M128.26M128.87M
Cost of Revenue61.94M72.2M75.28M86.41M88.57M
Gross Profit38.94M39.07M27.99M41.85M40.3M
Gross Margin38.6%35.1%27.1%32.6%31.3%
Research & Development6.68M7.84M8.74M8.58M8.26M
Selling, General & Admin27.72M34.66M38.97M40.46M44.05M
Operating Expenses47.76M50.86M49.78M50.69M57.54M
Depreciation & Amortization19.87M18.06M13.18M8M8.03M
EBITDA(987K)12.84M(33.17M)35.6M(8.81M)
EBITDA Margin-1.0%11.5%-32.1%27.8%-6.8%
Operating Income(8.82M)(11.79M)(21.8M)(8.84M)(17.25M)
Operating Margin-8.7%-10.6%-21.1%-6.9%-13.4%
Interest Income48K81K68K00
Interest Expense8.93M15.55M17.65M18.09M21.84M
Other Income / Expenses(20.96M)(8.9M)(42.13M)18.36M(21.43M)
Income Before Tax(29.79M)(20.69M)(63.93M)9.51M(38.67M)
Pre-Tax Margin-29.5%-18.6%-61.9%7.4%-30.0%
Income Tax Expense(6.35M)(5.21M)308K183K43K
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Net Margin-32.0%-104.9%-96.4%9.4%-30.0%
EPS (Basic)(1.12)(3.97)(3.32)0.39(1.27)
EPS (Diluted)(1.12)(3.97)(3.32)0.33(1.27)
Weighted Avg Shares29.29M29.47M29.96M30.47M34.82M
Weighted Avg Shares (Diluted)29.29M29.47M29.96M36.66M34.82M

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.